EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant.

Funding Source: FDA OOPD
Epstein-Barr Virus Infections|Primary Immune Deficiency Disorder
DRUG: cytotoxic t-lymphocytes
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Patients will be monitored for adverse events related to the infusion of EBV CTLs, Patients will be followed for 12 weeks after each infusion|Incidence of Response to Treatment [Efficacy], Patients will be followed for improvement in viral infection by monitoring EBV PCR weekly for response to treatment with CTLs, Patients will be followed for 12 weeks after each infusion
Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant.

Funding Source: FDA OOPD